- Kaiser Permanente names SVP, Fresno service area manager
- Nebraska hospital CEO resigns amid allegations of $38K in improper spending
- Northwell’s direct contracting business wants to ‘link up’ with other health systems
- PDS Health among 1st to deploy Epic-integrated AI platform
- CommonSpirit’s 5 targets for judging payer prior auth reform — and its Humana milestone
- LifeBridge names division president
- Private equity struggles in healthcare amid mounting pressures: 5 notes for dentistry
- Who’s actually winning the fight for ASC ownership?
- Why some ASCs are buying their own anesthesia groups
- Hospital Sisters Health System names chief technology officer
- Top Medicare Advantage plans for member satisfaction in 2026: JD Power
- How a 12-hospital system saved millions with an inventory overhaul
- Corporate medicine is burning out 90% of employed physicians: 10 survey findings
- HCA Florida hospital names assistant CFO
- GE HealthCare taps new CFO
- 6-property outpatient portfolio acquired
- Patients deserve every evidence-based option for mental healthcare
- 10 anesthesia controversies in 2026
- The $314K cost of employing a physician
- Who’s driving physician M&A in 2026? 5 deals to know
- 5 ways insurers are undercutting anesthesia payments: ASA
- Prior GLP-1 use doesn’t affect bariatric surgery results: 6 things to know
- Statement on Regulation Crypto Assets: Fit-for-purpose Exemptions for Crypto Market Innovation
- Filling the Regulatory Tank: Regulation Crypto Assets Proposing Release
- Statement on Regulation Crypto Assets
- Dental therapy program enrollment up 533% in 5 years
- Dental assisting program enrollment down 5.2% in 5 years
- Dental hygiene program enrollment up 15% in 5 years
- Surgery Partners ditches its $200M M&A target in favor of de novo growth: 5 things to know
- The dental specialties DSOs will prioritize next
- Statement on Commencement of Appointment Process for Public Company Accounting Oversight Board Seat
- Dental school enrollment in the 10 states with the most dental shortage areas
- How To Protect Yourself During Wildfire Season
- Ballmer Institute lands $125M to expand child behavioral health training nationwide
- Judge weighs whether man charged with killing dentist can act as own attorney
- FDA Seeks Public Feedback to Inform Regulatory Approach for Generative AI-Enabled Medical Devices
- Included Health to offer Carrum specialty care for alternative plan members
- 52 behavioral health executive moves to know
- Hospital performance improves in June, but lags 2025
- University of Toledo gets nearly $2M to support behavioral health workforce
- CTA reporting requirements eliminated for most dental practices: 5 things to know
- National Alliance on Mental Illness names chief medical officer
- Pennsylvania opens 24/7 behavioral health crisis center
- Cyber criminals target DSOs, dental groups: 3 updates
- OpenAI boosts mental health safeguards for teens
- UnitedHealthcare expands behavioral coaching to 13 million members
- Kindergarten Vaccine Exemptions Hit Record High, New CDC Data Shows
- Loneliness Is A Health Crisis, But Doctors Alone Can't Cure It, Analysis Argues
- Ousted OHSU Healthcare CEO files lawsuit alleging wrongful termination, discrimination
- JD Power: Member satisfaction with Medicare Advantage plans continues to slide
- AMA applauds updated CMS prior authorization reporting guidance
- Constipation In Space: A New Study Provides Answers
- Social Media Beauty Trends May Up Teens' Exposure To Hormone-Disrupting Chemicals
- HIPAA-compliant marketing platform Ours Privacy lands $15M amid growing pixel concerns
- Pharma commercialization partner Valeris brings in new strategy chief
- Biokin bispecific ADC iza-bren hits goal in lung cancer trial, boosting case for BMS’ global test
- CSL shares up 17% as immunoglobulin boost points to signs of recovery
- R1 acquiring Humata Health to bolster AI-powered prior authorizations
- Revance hires Janelle Wichmann as chief marketing officer of skincare unit
- CMI adopts orphan drug field with dedicated center of excellence
- Waist Size Is Accurate Way To Gauge Unhealthy Excess Weight, Study Says
- Panel Offers First Guidelines For Using E-Cigarettes To Help Smokers Quit
- Celcuity keeps cool amid questions about Revtorpyk launch timing
- Newsom Promotes Affordable Insulin, But California's Generic Label Off To A Slow Start
- What Geriatric Emergency Departments Do Differently
- Drive for Nuclear Power Boosts Uranium Industry — And Tribal Health Concerns in Southwest
- Rural primary care company Hopscotch clinches $53M to expand beyond NC
- Eurofins expands operations to meet growing high-potency API demand
- 24 new behavioral health projects to know
- Four health systems, including Ochsner and Denver Health, go live with Epic's real-time prior authorization checks
- 8 new psychiatric residency programs to know
- DocGo agrees to acquire virtual care provider Hicuity Health, assumes $52M debt
- Papa, eternalHealth expand partnership around Plus platform
- Happy Health secures $75M to expand AI-powered care in the home starting with sleep apnea
- As healthcare costs weigh on patients, states could play a bigger role, report finds
- Jalapeño Recalls Keep Growing As Salmonella Outbreak Investigation Continues
- Music Streaming Linked To Rise In Traffic Deaths
- EyePoint shares plummet after phase 3 stumble for AMD drug-device combo Duravyu
- Quanovate takes back marketing claims for Mira fertility wand after P&G challenge
- Sanofi to lay off 229 Blueprint Medicines staffers, close Cambridge offices following acquisition
- Whoop expands Advanced Labs to non-members, adds Grail’s multi-cancer detection test to lineup
- Quartz Countertop Workers Are Falling Prey To Lung Disease
- Kaiser Permanente notches 4.6% Q2 operating margin, $5.3B net income
- Epic faces Federal Trade Commission antitrust investigation, Reuters reports
- Innovaccer, Mastek ink strategic partnership to scale agentic AI in healthcare globally
- Sandoz strikes $322M biosimilars deal with Shanghai Henlius
- Argenx heads to FDA with Vyvgart after ph. 3 win in potential blockbuster autoimmune indication
- Many Smokers Unaware Of Heart, Brain Risks Of Smoking
- Tylenol, Other Medications Fuel Spike In Liver Damage Cases, Poison Center Data Says
- AstraZeneca touts Enhertu, Orpathys dual lung cancer wins amid bispecific failure
- My Husband Was Kicked Out Of Hospice For Dying Too Slowly
- Tadalafil (Cialis), Used for BPH and ED, Might Increase Glaucoma Risk, Study Says
- Kennedy’s Quiet Hunt for Autism Culprits Stalls as Trump Orders Baseless Changes to Childhood Shots
- Newsom Promotes Affordable Insulin, but California’s Generic Label Off to a Slow Start
- Inside agency view: Real Chemistry’s Frank Mazzola on audience nuance and rewarding creativity
- Abridge expands AI decision support to more clinicians in bid to become healthcare's copilot
- Danish politicians call out Eli Lilly obesity campaign
- Universal Health Services closes $835M Talkspace acquisition
- Gounder Brings Clarity to Egg Freezing, AI Virus Creation, and New Trump Vaccine Order
- States Enact Emergency Orders On Kratom While Awaiting Federal Rules
- Study examines how ICHRA adoption could help stabilize ACA risk pools
- Winter Is Coming: How Vaccines Help Protect Against Respiratory Illness
- Screen Time Is Not All Bad For Kids' Brains
- Processed Foods Linked To Prostate Cancer Risk
- Updated Statement Regarding the Division of Corporation Finance’s Role in the Exchange Act Rule 14a-8 Process
- It's BMS vs. Celgene investors once more after US appeals court revives lawsuit
- Industry Voices—AI should help cancer patients survive the healthcare system
- Tavneos trial flagged for 'serious breaches' of protocol as EU regulators dissect market withdrawal decision
- Sleep Disturbances Linked To Genetic Alzheimer's Risk
- Pre-K Sets Kids Up For School Success, Study Says
- Expect Other Seniors To Act Their Age? Then Expect Problems With Your Own Memory, Study Says
- A genomics library for the AI era
- BMS bags first FDA approval for CELMoD franchise with Zenbexus multiple myeloma nod
- People With Disabilities Say Medicaid Income Limits Stifle Career Advancement
- Trump Team’s Use of Arcane Budget Rule Threatens Medicaid Coverage
- My Husband Was Kicked Out of Hospice for Dying Too Slowly
- Fierce Pharma Asia—Legend’s first profit; Taiho, Cullinan’s EGFR win; WuXi AppTec’s reprieve
- Rare Bacteria In Coastal Waters Has Killed 7 This Summer
- It's crunch time for Karyopharm as company faces potential default next month
- Socializing: A Prescription For Healthier Brain Aging
- Taking The Stairs May Lower Your Risk Of Dying From Heart Disease
- AZ's blood pressure newcomer Baxfendy fails to meet cost-effectiveness bar, ICER says
- How consumerization is reshaping pharma marketing
- Sweet Tooth? It Could Be Shaping Your Decisions, Study Says
- Stressed Parents Turn To Screens For Help, Study Finds
- Gambling Linked To Mental Health Problems Among College Students
- Hospitals Say They Found A Tool To Help Reduce Childbirth Risks: Wristbands
- Listen to the Latest ‘KFF Health News Minute’
- Readers Speak Out on Work Requirements, Federal Data Grab, Opioid Payback Cash
- People With Disabilities Say Medicaid’s Limits on Income Stifle Career Advancement
- FDA Wants More Information From Food Makers On New Food Chemicals
- Aspirin/Omega-3 Combo Matches Antibiotics In Treating Gum Disease, Trial Finds
- Endometriosis Linked To Higher Type 2 Diabetes Risk
- Beyond Compliance: Rethinking No Surprises Act strategy
- Tamiflu Helps Keep Severely Ill Kids Out Of The ICU, Study Finds
- 'Normal' Can Backfire During Doctor/Patient Discussions
- Experimental Pulse Oximeter Accurate Regardless Of Skin Tone, Researchers Say
- Patients Wary Of Governments, Companies Pushing AI As A Rural Healthcare Solution
- Executive Order Calls For Fewer Routine Childhood Vaccines, Doctors Push Back
- Real-World Performance Of Alzheimer's Drug, Leqembi, Matches Trial Data, Study Finds
- Study Finds Undisclosed Chemicals In Most Personal Care Products
- Chairman Paul S. Atkins Letter to Robert Walley, Chair, CAT NMS Plan Operating Committee
- What 524B and QMSR Change About Medical Device Risk
- Taking Lean Manufacturing to the Next Level
- Why Few MedTech Sales Teams Are Using AI Where It Matters Most
- Why Organizations Miss Emerging Product Risk: Understanding the engineering mechanisms that remain hidden long before complaint trends become visible
- Update on the SEC’s Work Toward Treasury Clearing Implementation [August 2026]
- The Interface is the Risk: A MedTech Blueprint for AI and System Integration
- Restoring Regulatory Clarity: Statement on Technical Amendments to Rule 0‑1(a)(7)
- Beyond the Status Report: Using LLMs to Reveal the True State of SaMD Development
Michigan healthcare freedom community forum
AG Nessel is serving her financial paymasters at the Michigan Association for Justice (MAJ), who have been campaigning for the State Legislature to gut the Michigan Supreme Court (MSC)'s Smith v. Globe Life Ins. Co. and Liss v. Lewiston-Richards, Inc. decisions.
AG Nessel Asks Michigan Supreme Court to Correct Past Decisions, Allow Insulin Investigation
August 04, 2023
LANSING – Michigan Attorney General Dana Nessel this week filed an application seeking leave to appeal an order preventing her from proceeding with an investigation of Eli Lilly and Company’s insulin pricing practices. Lilly has used two past decisions of the Michigan Supreme Court (MSC) to assert the Michigan Consumer Protection Act (MCPA) is inapplicable to its sale of insulin. The Attorney General is asking the Supreme Court to reverse those decisions because they are not supported by a plain reading of the law.
In January 2022, Nessel launched an investigation into Eli Lilly - one of the nation’s three largest drug-manufacturing companies producing insulin. The action sought to use the MCPA to investigate various aspects of Lilly’s pricing practices related to life-saving medications used by diabetics. Nessel also filed a companion Complaint for Declaratory Judgment, asking the court to declare that MCL 445.904(1)(a) does not prohibit an investigation into Eli Lilly’s insulin pricing. But Lilly used the two prior decisions to obtain an order stating that the consumer protection act does not apply to its insulin sales, thus halting the investigation.
“The Smith v. Globe Life Ins. Co. and Liss v. Lewiston-Richards, Inc. decisions have been used to frustrate consumer protection efforts for far too long,” Nessel said. “It is unconscionable for Michigan residents to have to choose between life-saving medicine and food or rent. My Consumer Protection Team stands ready to hold drug companies accountable for their unjustifiable prices, but we can only do so if we are not being hindered by court decisions that misapply the text of a law having a purpose obvious from its name.”
Last July, Ingham Circuit Judge Wanda M. Stokes granted Lilly’s motion for summary disposition, holding that the Smith v. Globe Life Ins. Co. and Liss v. Lewiston-Richards, Inc. decisions preclude application of the MCPA to Lilly’s sale of insulin medications because the general transaction of selling insulin is authorized by the Food and Drug Administration.
A claim of appeal was filed with the Court of Appeals (COA) along with a bypass application to the MSC. The MSC denied the bypass application but asked the COA to expedite the appeal. The COA upheld the lower court’s decision, leading to this week’s filing.
Smith (1999) and Liss (2007) interpret an exemption contained in Section 445.904(1)(a) of the MCPA as applying whenever the general transaction is specifically authorized by law, regardless of whether the specific misconduct alleged is prohibited. Under this interpretation, members of any industry that is generally regulated are often deemed exempt from the MCPA, thereby providing what is effectively a “free pass” for misconduct under the MCPA, regardless of how egregious the misconduct.
The Attorney General’s appeal is not based on the merits of whether Eli Lilly has violated the MCPA, but rather on the Attorney General’s authority to investigate possible MCPA violations under MCL 445.907 when Eli Lilly is generally authorized to sell insulin medications by the Food and Drug Administration (FDA) but is bound by no FDA regulations regarding the pricing of those medications.
The MCPA was enacted in 1976 and Attorney General Nessel is hopeful the legislature will take action to update the statute.
“Without the ability to wield the full authority provided by the act, my department is hobbled in its ability to investigate and hold accountable many regulated entities that may be ripping off Michigan consumers,” Nessel continued.
“In order for the Department of Attorney General to be the people’s watchdog when it comes to investigating the costs of prescription drugs, we must breathe life back into the Michigan Consumer Protection Act and revive the law’s original purpose to protect consumers. I look forward to working with the legislature to see that these critical changes are made to the statute.”
The Centers for Disease Control estimates that there are 34.2 million Americans with diabetes. In Michigan, the American Diabetes Association estimates that 865,000 people, or 11.2% of the adult population, have diabetes and that those with diabetes have medical expenses approximately 2.3 times higher than those who do not.
Those who wish to share their experience with the high cost of insulin are asked to fill out a consumer complaint form on the Attorney General's website. The Attorney General is interested in perspectives from consumers, pharmacists, and health professionals. If your concerns relate to the cost of a particular medication, please tell us the brand, product, and what (if anything) is covered by insurance.
Politics of greed. 😪
This is a battle of the lower depths. The real answer to high drug prices is more competition, not shifting profits from Big Pharma to parasitic lawyers.
This is true. It takes lawyers to produce this level of spin!
Michigan's Democrat-controlled Supreme Court heard Attorney General v Eli Lilly and Co (165961) yesterday. Attorney General Nessel is alleging that Eli Lilly's insulin pricing practices violate the Michigan Consumer Protection Act (MCPA). A three judge panel of the Michigan Court of Appeals threw out this case, but it appears that the Democrats on the Supreme Court want to reinstate it. We covered AG Nessel's initiation of this lawsuit two years ago in AG Nessel Seeks Reversal Of Michigan Supreme Court Rulings To Permit Investigation Of Eli Lilly Insulin Pricing:
The Case SummaryThe Attorney General seeks to investigate the cost of insulin medications manufactured by the defendant to determine whether the defendant’s pricing practices violate the Michigan Consumer Protection Act (MCPA). To that end, the Attorney General petitioned the Ingham Circuit Court for the issuance of civil investigative subpoenas under MCL 445.907. The Attorney General also filed a complaint seeking a declaratory judgment that the proposed investigation of the defendant’s pricing practices is not barred by the MCPA’s exemption for “transaction[s] or conduct specifically authorized under laws administered by a regulatory board or officer acting under statutory authority of this state or the United States.” MCL 445.904(1)(a). The complaint acknowledged that the Attorney General’s interpretation of the exemption is contrary to the construction given by the Supreme Court in Smith v Globe Life Ins Co, 460 Mich 446 (1999), and Liss v Lewiston-Richards, Inc, 478 Mich 203 (2007). The complaint alleged, however, that those cases were wrongly decided. The defendant moved for summary disposition under MCR 2.116(C)(8) (failure to state a claim), arguing that its transactions and conduct fall within the MCPA’s exemption based on the Smith and Liss decisions. The circuit court granted the motion and dismissed the Attorney General’s complaint. The Attorney General claimed an appeal of right in the Court of Appeals and then filed a bypass application in the Supreme Court. The Supreme Court denied the bypass application but directed the Court of Appeals to expedite its consideration of the case. The Court of Appeals affirmed the trial court in an unpublished opinion, holding that it was bound by Smith and Liss. The Supreme Court has ordered oral argument on the application to address: (1) whether the plaintiff adequately pled a claim that the defendant violated the Michigan Consumer Protection Act (MCPA), MCL 445.901 et seq.; (2) whether it is necessary for the plaintiff to adequately plead a violation of the MCPA for a court to determine whether MCL 445.904(1)(a), an exemption to the MCPA, applies; (3) whether this Court’s decisions in Smith v Globe Life Ins Co, 460 Mich 446 (1999), and Liss v Lewiston-Richards, Inc, 478 Mich 203 (2007), correctly interpreted MCL 445.904(1)(a); and (4) if they were incorrectly decided, whether they should nonetheless be retained under principles of stare decisis, Robinson v City of Detroit, 462 Mich 439, 463-468 (2000).
The Court of Appeals Dismissal:
The story from Michigan Advance:
Michigan Supreme Court hears argument in Nessel price gouging lawsuit against insulin drug maker
By Ben Solis - November 5, 2025Attorney General Dana Nessel’s ability to go after a major producer of insulin for price gouging was before the Michigan Supreme Court on Wednesday, with the state saying that it should be allowed to move forward in the matter despite previous court precedent noting otherwise.
Meanwhile, the attorney for the defendant in Attorney General v. Eli Lilly and Company said the attorney general’s office has failed to show an actual controversy exists and that this was an improper test case for the bounds of Michigan’s Consumer Protection Act.
The case centers around Nessel’s attempts to investigate the drug manufacturer to determine if its pricing practices for insulin violated the Michigan Consumer Protection Act. She asked the Ingham Circuit Court for subpoenas to gather information, and also filed a separate request for a judge to declare that her investigation wasn’t blocked by the act’s exemptions for activities already approved by government or regulatory agencies.
That motion noted that Nessel’s interpretation of the act was out of step with the Michigan Supreme Court’s decisions in Smith v. Globe Life Insurance Company and Liss v. Lewiston-Richards Inc. Nessel has asserted that both of those cases were wrongly decided.
The appellate court affirmed the circuit court’s decision to dismiss the case in an unpublished opinion, which means the opinion was not binding on the lower courts or necessarily instructive to the Michigan Supreme Court.
In court on Wednesday, Assistant Attorney General Darrin Fowler reupped those arguments, and asked the justices of the high court to reconsider its previous findings in those cases, as well as for a determination if the case can be ferreted out in state court using the consumer protection act.
A key part of that is showing the court that there has been an adversarial relationship between the two parties and that it was a dispute for the court to take up.
“Here, the Attorney General was not required to bring an investigative petition to launch an insulin investigation into Eli Lilly,” Fowler said. “What the attorney general was required to do under the declaratory judgment rule was to give evidence of a sincere intention to invoke the consumer protection act against Lilly in a way that would be adversarial and would implicate the section for exemption”
Fowler added that the office has spent nearly four years arguing about the Smith and Liss issues from the circuit court up to the Court of Appeals, and now before the state’s high court.
The bigger picture, Fowler said, was that the company is misconstruing the act and its requirement to show probable cause that a method or practice in pricing was unlawful.
Eli Lilly has said that the attorney general’s office engaged in a poor read of the act, an assertion that led the lower court to dismiss the case.
John O’Quinn, attorney for Eli Lilly, told the court that Smith and Liss were long-held precedent in consumer protection matters, and the Legislature has amended the act several times over. O’Quinn said that formed a “powerful chain” to show the high court, now, that the previous court’s decisions in those cases were correct.
“The Attorney General puts the cart before the horse in asking this court to decide the contours of an exemption, in the department’s words, an ‘affirmative defense’ as a threshold matter where the department has declined to show any legally viable violation has been alleged in the first place,” O’Quinn said. .
The case being mired in procedural intricacies led the justices to ask mostly technical questions about other cases that could or should be overturned and different ways those decisions might have been attacked by the attorney general, instead of insisting it could move forward under the consumer protection act.
But Chief Justice Megan Cavanagh pointedly asked Fowler if the manufacturer could have appealed the lower court’s finding of probable cause, which led to the issue of subpoenas.
Fowler said that under the act, Eli Lilly had to start with a motion to quash, but the company opted not to do that. The company, instead, brought a motion to stay the case in the circuit court, which was a different argument than what was before the court on Wednesday.
Overall, Fowler said the state believed that the initial petition jump started the controversy, showing there was a tangible legal dispute for the court to parse.
Nessel, Singh react to court hearing
Following the hearing, Nessel, in a statement, doubled down on her office’s assertion that the decisions preclude state investigations into suspected illegal business practices when that business sells products or services authorized for sale under state or federal law. The attorney general’s office said that was irrespective of whether there was an allegation on how that business conducted its affairs.
“Eli Lilly has relied on these past Supreme Court decisions that twist a narrow exemption into something far too broad,” Nessel said. “The Michigan Consumer Protection Act is supposed to protect consumers, but instead it often shields many corporations from any real accountability, even when their business practices are clearly egregious. People in Michigan expect this law to have their back, and it is my hope that the Court sides with the consumers who have been hurt by deceptive practices.”
State Sen. Sam Singh (D-East Lansing), the Senate’s majority floor leader, said in a statement that Michigan has had “worst-in-the-nation consumer protection laws” for too long, which have “left residents across the state vulnerable to exploitation and fraudulent business practices – in this case, drug manufacturers profiting off of people’s pain.”
“While it’s my hope that the outcome of this case sets the dial in the right direction, we must also change the laws on our books to prioritize protections for consumers over corporations,” Singh said. “By restoring power to the Michigan Consumer Protection Act and giving more tools to the Attorney General’s office to hold bad actors accountable, my legislation would give Michiganders the peace of mind they deserve as they go about their day-to-day activities and purchases.”
Singh introduced Senate Bill 134 to help bolster Michigan’s consumer protection statute, which was passed by the Senate in June.
The bill now sits in the House Judiciary Committee and has not yet had a hearing.
AG Nessel Beats Eli Lilly 4 To 3 At The Michigan Supreme Court
The Democrats on our Michigan Soviet Supreme Court overturned two precedent setting decisions — Smith v. Globe Life Insurance Co. (1999) and Liss v. Lewiston-Richards Inc. (2007) — that have long blocked attorneys general from investigating businesses already regulated by another agency. The MSC opinion in Nessel v. Eli Lilly & Co. (MSC 165961) hasn't yet been posted on the Michigan Supreme Court web site, but the deatils are circulating. The only real surprise was the close vote, 4 to 3.
This decision was closely watched by business groups across the country. It will confirm Michigan's hostile business environment and subjugation to MAJ to many business leaders. That sucking sound is getting louder:
Michigan Supreme Court overturns cases that blocked insulin pricing investigation
By Madalyn Buursma, Brad LaPlante - August 1, 2026LANSING, Mich. (WLNS) — The Michigan Supreme Court on Friday sided with Michigan’s attorney general, overturning two previous decisions that could have kept her from investigating insulin prices.
In a 4-3 decision, it ruled in favor of Michigan Attorney General Dana Nessel over Eli Lilly and overturning an exemption under the Michigan Consumer Protection Act.
The fight traces back to January 2022, when Nessel launched an investigation into Eli Lilly’s insulin pricing practices under the state’s consumer protection laws, alleging it had artificially increased the price of insulin medication. The drug maker pushed back, citing two Michigan Supreme Court decisions — Smith v. Globe Life Insurance Co. (1999) and Liss v. Lewiston-Richards Inc. (2007) — that have long blocked attorneys general from investigating businesses already regulated by another agency.
GOP bill aims to shield regulated businesses from lawsuits
Eli Lilly is regulated by the Food and Drug Administration and the Michigan Board of Pharmacy. Neither agency has authority over drug pricing.
An Ingham County Circuit Court judge sided with Eli Lilly in 2022, and the Michigan Court of Appeals upheld that ruling. Nessel appealed to the state Supreme Court, which heard oral arguments in November.
In Friday’s ruling, the court overturned both Smith v. Globe Life Insurance Co. and Liss v. Lewiston-Richards Inc.
Nessel in a statement celebrated the ruling, saying the state’s Consumer Protection Team “can go back to helping residents who have been deceived by licensed businesses.”
“Today is a great day for Michigan residents, and I am profoundly relieved that the Michigan Supreme Court finally restored the Consumer Protection Act to its true purpose,” she ruled. “What was once rendered toothless can now protect the people of our state who fall victim to predatory commercial operators.”
The Michigan Alliance for Legal Reform in a release said the decision exposes industries to “overlapping regulations, greater uncertainty, abusive litigation, and higher costs.”
“Today’s decision upends decades of settled case law, exposing workers and job providers alike to abusive litigation, duplicative red tape, and higher costs that will ultimately be passed along to Michigan consumers,” Zach Rudat, director of the Michigan Alliance for Legal Reform, said in a statement. “The Legislature must act now to codify the regulatory compliance exemption and restore clear, predictable standards for those already operating under extensive government oversight.”
The organization advocated for House Bill 5725. The bill, introduced by State Rep. Bill G. Schuette, R-Midland, would write a so-called “regulatory compliance exemption” directly into Michigan’s Consumer Protection Act.
Schuette previously said if the exemption is weakened, tradespeople and small businesses would be exposed to “tremendous amounts of litigation from money-hungry trial lawyers.”
Gov. Gretchen Whitmer in a social media post called Friday’s decision a “landmark victory for Michigan consumers.”
“This can protect consumers from predatory practices like needlessly raising the price of insulin,” she wrote. “For decades, Michiganders, unlike consumers in nearly every state, lacked an effective way to hold businesses accountable for unfair practices. I congratulate Attorney General Nessel on this win.”
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.























